A 2026 systematic review has concluded that administering sucrose to newborns likely reduces pain during venepuncture, the medical procedure used to draw blood from infants. The findings offer clinicians fresh evidence supporting the use of a simple, low-cost intervention to manage procedural pain in one of medicine's most vulnerable patient populations. The review analyzed data from multiple studies comparing sucrose against placebos, water, and no treatment at all.
Researchers found that newborns given sucrose before and during venepuncture probably experienced significantly less pain both during the procedure and in the immediate period following it. The comparison groups — infants who received nothing, plain water, or a non-active substitute — showed notably higher indicators of pain response. Pain in newborns is typically measured through validated tools that assess facial expressions, cry duration, and physiological responses such as heart rate changes.
Venepuncture is one of the most frequently performed painful procedures in neonatal care, used for routine blood tests, metabolic screenings, and monitoring of critically ill infants. Despite its frequency, pain management protocols for newborns during such procedures have historically varied widely across hospitals and health systems. Untreated procedural pain in neonates has been associated with potential long-term developmental and neurological consequences, making effective pain relief a priority in newborn care.
The review's findings add weight to existing guidance from several pediatric and neonatal healthcare bodies that have previously recommended sucrose as a non-pharmacological pain management option. Sucrose is believed to activate endogenous opioid pathways in the brain, producing a mild analgesic effect when administered orally in small quantities prior to a painful procedure. The intervention is considered safe, inexpensive, and easy to administer in both hospital and clinical settings.
Despite the encouraging results, the systematic review authors noted that the overall quality of evidence remains an important consideration for clinical interpretation. Variability in study design, sucrose concentration, timing of administration, and pain measurement tools across individual studies may affect the certainty of the conclusions. Researchers called for further well-designed randomized controlled trials to strengthen the evidence base and refine dosing recommendations.
Healthcare professionals and neonatal care advocates are expected to point to the review as further justification for standardizing sucrose use across neonatal units globally. The findings are particularly relevant for low- and middle-income settings where pharmacological pain relief options may be limited or unavailable. Medical bodies are likely to review their existing pain management guidelines in light of the new evidence to ensure consistent, evidence-based care for newborns undergoing routine but painful procedures.
